Literature DB >> 32076933

Identification of Dysfunctional Gut Microbiota Through Rectal Swab in Patients with Different Severity of Acute Pancreatitis.

Shanshan Yu1, Yangyang Xiong2, Jun Xu1, Xianquan Liang3, Yangyang Fu1, Danyu Liu1, Xuezhong Yu1, Dong Wu4.   

Abstract

BACKGROUND: Acute pancreatitis (AP) has a wide spectrum of severity and can be associated with considerable morbidity and mortality. Whether gut microbiota dysbiosis is associated with AP severity remains obscure. AIMS: We aim to investigate the differences in the alterations of gut microbiota in different grades of AP severity.
METHODS: We collected clinical information and rectal swab samples from 80 individuals. The gut microbiota was tested by 16S rRNA gene sequencing, gut microbiota species composition analysis, difference analysis, random forest model prediction analysis, and gut microbiota species correlation network analysis.
RESULTS: There was a different microbiota profile in different severity grades. Bacteroides, Escherichis-Shigella, and Enterococcus were dominant species in mild, moderately severe, and severe AP, respectively. Finegoldia was the most significantly increased and Blautia the most decreased species in mild AP. Anaerococcus was the most significantly increased and Eubacterium hallii the most decreased species in moderately severe AP. Enterococcus was the most significantly increased and Eubacterium hallii the most decreased species in severe AP. Finegoldia, Eubacterium_hallii, and Lachnospiraceae were potential diagnostic biomarkers for mild AP and Eubacterium_hallii and Anaerococcus for moderately severe AP. There was a positive interaction between Firmicutes and Bacteroidetes in mild AP.
CONCLUSIONS: The disturbed gut microbiota is different among grades of AP, suggesting their potential role in the progression of disease severity. There was a different microbiota profile in different severity grades. Bacteroides, Escherichis-Shigella, and Enterococcus were dominant gut microbiota species in MAP, MSAP, and SAP, respectively. Finegoldia was the most significantly increased and Blautia the most decreased gut microbiota species in MAP. Anaerococcus was the most significantly increased and Eubacterium hallii the most decreased species in MSAP. Enterococcus was the most significantly increased and Eubacterium hallii the most decreased species in SAP. Finegoldia, Eubacterium_hallii, and Lachnospiraceae were potential diagnostic biomarkers for MAP and Eubacterium_hallii and Anaerococcus for MSAP. There was a positive interaction between Firmicutes and Bacteroidetes in MAP.

Entities:  

Keywords:  Acute pancreatitis; Diagnostic biomarkers; Gut microbiota; Microbiota dysbiosis; Severity

Mesh:

Year:  2020        PMID: 32076933     DOI: 10.1007/s10620-020-06061-4

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  17 in total

1.  Microbiome changes associated with acute and chronic pancreatitis: A systematic review.

Authors:  L Brubaker; S Luu; Kl Hoffman; A Wood; M Navarro Cagigas; Q Yao; Jf Petrosino; W Fisher; G Van Buren
Journal:  Pancreatology       Date:  2020-12-23       Impact factor: 3.996

2.  Clinical characteristics and outcome of tumor-associated acute pancreatitis: a single-center cohort study.

Authors:  Yangyang Xiong; Yi Zhao; Xianlin Han; Guorong Chen; John Windsor; Dong Wu; Jiaming Qian
Journal:  Ann Transl Med       Date:  2021-04

3.  Pretreatment with chitosan oligosaccharides attenuate experimental severe acute pancreatitis via inhibiting oxidative stress and modulating intestinal homeostasis.

Authors:  Qi-Xiang Mei; Jun-Hui Hu; Ze-Hua Huang; Jun-Jie Fan; Chun-Lan Huang; Ying-Ying Lu; Xing-Peng Wang; Yue Zeng
Journal:  Acta Pharmacol Sin       Date:  2021-01-25       Impact factor: 7.169

4.  Parabacteroides produces acetate to alleviate heparanase-exacerbated acute pancreatitis through reducing neutrophil infiltration.

Authors:  Yuanyuan Lei; Li Tang; Shuang Liu; Shiping Hu; Lingyi Wu; Yaojiang Liu; Min Yang; Shengjie Huang; Xuefeng Tang; Tao Tang; Xiaoyan Zhao; Israel Vlodavsky; Shuo Zeng; Bo Tang; Shiming Yang
Journal:  Microbiome       Date:  2021-05-20       Impact factor: 14.650

Review 5.  Gut Dysbiosis in Pancreatic Diseases: A Causative Factor and a Novel Therapeutic Target.

Authors:  Tao Zhang; Guangqi Gao; Hafiz Arbab Sakandar; Lai-Yu Kwok; Zhihong Sun
Journal:  Front Nutr       Date:  2022-02-15

6.  The Mucosally-Adherent Rectal Microbiota Contains Features Unique to Alcohol-Related Cirrhosis.

Authors:  Ting-Chin David Shen; Scott G Daniel; Shivali Patel; Emily Kaplan; Lillian Phung; Kaylin Lemelle-Thomas; Lillian Chau; Lindsay Herman; Calvin Trisolini; Aimee Stonelake; Emily Toal; Vandana Khungar; Kyle Bittinger; K Rajender Reddy; Gary D Wu
Journal:  Gut Microbes       Date:  2021 Jan-Dec

7.  Sodium Butyrate Attenuates Taurocholate-Induced Acute Pancreatitis by Maintaining Colonic Barrier and Regulating Gut Microorganisms in Mice.

Authors:  Yangyang Xiong; Li Ji; Yi Zhao; Ailing Liu; Dong Wu; Jiaming Qian
Journal:  Front Physiol       Date:  2022-03-17       Impact factor: 4.566

8.  Variations in Gut Microbiome are Associated with Prognosis of Hypertriglyceridemia-Associated Acute Pancreatitis.

Authors:  Xiaomin Hu; Liang Gong; Ruilin Zhou; Ziying Han; Li Ji; Yan Zhang; Shuyang Zhang; Dong Wu
Journal:  Biomolecules       Date:  2021-05-06

9.  Assessment of the course of acute pancreatitis in the light of aetiology: a systematic review and meta-analysis.

Authors:  Emese Réka Bálint; Gabriella Fűr; Lóránd Kiss; Dávid István Németh; Alexandra Soós; Péter Hegyi; Zsolt Szakács; Benedek Tinusz; Péter Varjú; Áron Vincze; Bálint Erőss; József Czimmer; Zoltán Szepes; Gábor Varga; Zoltán Rakonczay
Journal:  Sci Rep       Date:  2020-10-21       Impact factor: 4.379

Review 10.  Microbiota in Pancreatic Diseases: A Review of the Literature.

Authors:  Tommaso Schepis; Sara S De Lucia; Enrico C Nista; Vittoria Manilla; Giulia Pignataro; Veronica Ojetti; Andrea Piccioni; Antonio Gasbarrini; Francesco Franceschi; Marcello Candelli
Journal:  J Clin Med       Date:  2021-12-17       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.